(searched for: 10.29328/journal.apcr.1001010)
Published: 14 December 2018
Archives of Pathology and Clinical Research, Volume 2, pp 049-093; https://doi.org/10.29328/journal.apcr.1001010
Published: 1 July 2006
Journal of Environmental Engineering and Science, Volume 5, pp 335-348; https://doi.org/10.1139/s06-016
Air pollution control residues (APCR) from municipal waste incinerators are usually considered as hazardous wastes because of their high contents in easily soluble Pb and other toxic metal contaminants. The objective of this research was to compare various techniques using Pb adsorption on Sphagnum peat moss (MT) for the treatment of alkaline leachates produced during the decontamination of various types of APCR including used lime (CU), electrofilter ashes (CE), and boiler ashes (CC). Regeneration tests of saturated MT using hydrochloric and sulphuric acids have revealed that excessive acid consumption (>250 kg acid/metric ton of treated APCR) are necessary for the elution of metals. However, the incineration of the saturated MT and its possible valorization represents an interesting way to explore for the management of the adsorbent. This method allows to reduce by a factor of 3 or 4 the mass of residues and increases in the same proportion the Pb content in the incinerated MT. Finally, the present study has highlighted that ion exchange on the anionic functional groups of MT would be one of the most important mechanisms implied in the Pb fixation on this natural sorbent during the treatment of very alkaline leachates (pH > 11) of APCR.Key words: lead, leaching, incinerator, air pollution control residues (APCR), removal, peat, adsorption, toxicity characteristic leaching procedure (TCLP).[Journal translation]
American Journal of Hypertension, Volume 13, pp 61-65; https://doi.org/10.1016/S0895-7061(99)00140-5
This study was designed to investigate both resistance to activated protein C (APC-R) and the factor FV Q506 mutation incidence in patients with a history of acute myocardial infarction (AMI) and patients with primary hypertension (PH), a high-risk group for arterial thrombosis. Eighty patients with a history of AMI (group A), 160 patients with a history of PH (group B), and 124 age-matched controls without arterial disease (group C) were studied. APC-R was determined using the Coatest APC Resistance Kit of Chromagenix, Sweden. The prevalence of the FV Q506 mutation was estimated by DNA analysis (Bertina method). The prevalence of the FV Q506 mutation was 20%, 13.75%, and 8% in groups A, B, and C, respectively (A v C P .0466). The prevalence of APC-R was 47.5% in group A v 13% in group C (P< .0001) and 36.25% in group B v 13% in group C (P< .0001). The response to activated protein C expressed as mean value ± SD was 2.05 ± 0.33 in group A v 2.56 ± 0.46 in group C (P< .05) and 2 ± 0.22 in group B v 2.56 ± 0.46 in group C (P< .05). These findings suggest that patients with a history of AMI or PH have a significantly increased incidence of both APC-R and FV Q506 mutation compared with the control group. These findings support the hypothesis that these anticoagulant defects may be risk factors for arterial thrombosis. Am J Hypertens 2000;13:61–65 © 2000 American Journal of Hypertension, Ltd.